EGFR and KRAS mutations in metastatic lung adenocarcinomas
Authors:
- Shuko HaradaSHShuko Harada
- Christina AdamsCAChristina Adams
- Frederic AskinFAFrederic Askin
- Douglas ClarkDCDouglas Clark
- Edward GabrielsonEGEdward Gabrielson
- Qing Kay LiQLQing Kay Li
- 1 October 2011
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 42 (10) , 1447-1453
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancerNeuro-Oncology, 2010
- Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS MutationsThe Journal of Molecular Diagnostics, 2010
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding MetastasesClinical Cancer Research, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLCBritish Journal of Cancer, 2008
- Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant KrasProceedings of the National Academy of Sciences, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004